Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.

Macfarlane S, Grimmer T, Teo K, O'Brien TJ, Woodward M, Grunfeld J, Mander A, Brodtmann A, Brew BJ, Morris P, Short C, Kurrle S, Lai R, Bharadwaj S, Drysdale P, Sturm J, Lewis SJG, Barton D, Kalafatis C, Sharif S, Perry R, Mannering N, MacSweeney JE, Pearson S, Evans C, Krishna V, Thompson A, Munisamy M, Bhatt N, Asher A, Connell S, Lynch J, Rutgers SM, Dautzenberg PL, Prins N, Oschmann P, Frölich L, Tacik P, Peters O, Wiltfang J, Henri-Bhargava A, Smith E, Pasternak S, Frank A, Chertkow H, Ingram J, Hsiung GR, Brittain R, Tartaglia C, Cohen S, Villa LM, Gordon E, Jubault T, Guizard N, Tucker A, Kaufmann WE, Jin K, Chezem WR, Missling CU, Sabbagh MN.

Open source

DOI: 10.1016/j.tjpad.2024.100016
Published: 2025-01-01
Container: J Prev Alzheimers Dis
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2024.100016,
  title = {Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.},
  author = {Macfarlane S and  Grimmer T and  Teo K and  O'Brien TJ and  Woodward M and  Grunfeld J and  Mander A and  Brodtmann A and  Brew BJ and  Morris P and  Short C and  Kurrle S and  Lai R and  Bharadwaj S and  Drysdale P and  Sturm J and  Lewis SJG and  Barton D and  Kalafatis C and  Sharif S and  Perry R and  Mannering N and  MacSweeney JE and  Pearson S and  Evans C and  Krishna V and  Thompson A and  Munisamy M and  Bhatt N and  Asher A and  Connell S and  Lynch J and  Rutgers SM and  Dautzenberg PL and  Prins N and  Oschmann P and  Frölich L and  Tacik P and  Peters O and  Wiltfang J and  Henri-Bhargava A and  Smith E and  Pasternak S and  Frank A and  Chertkow H and  Ingram J and  Hsiung GR and  Brittain R and  Tartaglia C and  Cohen S and  Villa LM and  Gordon E and  Jubault T and  Guizard N and  Tucker A and  Kaufmann WE and  Jin K and  Chezem WR and  Missling CU and  Sabbagh MN.},
  year = {2025},
  journal = {J Prev Alzheimers Dis},
  doi = {10.1016/j.tjpad.2024.100016},
  url = {https://doi.org/10.1016/j.tjpad.2024.100016}
}

RIS

TY  - JOUR
TI  - Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
AU  - Macfarlane S
AU  -  Grimmer T
AU  -  Teo K
AU  -  O'Brien TJ
AU  -  Woodward M
AU  -  Grunfeld J
AU  -  Mander A
AU  -  Brodtmann A
AU  -  Brew BJ
AU  -  Morris P
AU  -  Short C
AU  -  Kurrle S
AU  -  Lai R
AU  -  Bharadwaj S
AU  -  Drysdale P
AU  -  Sturm J
AU  -  Lewis SJG
AU  -  Barton D
AU  -  Kalafatis C
AU  -  Sharif S
AU  -  Perry R
AU  -  Mannering N
AU  -  MacSweeney JE
AU  -  Pearson S
AU  -  Evans C
AU  -  Krishna V
AU  -  Thompson A
AU  -  Munisamy M
AU  -  Bhatt N
AU  -  Asher A
AU  -  Connell S
AU  -  Lynch J
AU  -  Rutgers SM
AU  -  Dautzenberg PL
AU  -  Prins N
AU  -  Oschmann P
AU  -  Frölich L
AU  -  Tacik P
AU  -  Peters O
AU  -  Wiltfang J
AU  -  Henri-Bhargava A
AU  -  Smith E
AU  -  Pasternak S
AU  -  Frank A
AU  -  Chertkow H
AU  -  Ingram J
AU  -  Hsiung GR
AU  -  Brittain R
AU  -  Tartaglia C
AU  -  Cohen S
AU  -  Villa LM
AU  -  Gordon E
AU  -  Jubault T
AU  -  Guizard N
AU  -  Tucker A
AU  -  Kaufmann WE
AU  -  Jin K
AU  -  Chezem WR
AU  -  Missling CU
AU  -  Sabbagh MN.
PY  - 2025
JO  - J Prev Alzheimers Dis
DO  - 10.1016/j.tjpad.2024.100016
UR  - https://doi.org/10.1016/j.tjpad.2024.100016
ER  -

APA

S, M., T, G., K, T., TJ, O., M, W., J, G., A, M., A, B., BJ, B., P, M., C, S., S, K., R, L., S, B., P, D., J, S., SJG, L., D, B., C, K., S, S., R, P., N, M., JE, M., S, P., C, E., V, K., A, T., M, M., N, B., A, A., S, C., J, L., SM, R., PL, D., N, P., P, O., L, F., P, T., O, P., J, W., A, H., E, S., S, P., A, F., H, C., J, I., GR, H., R, B., C, T., S, C., LM, V., E, G., T, J., N, G., A, T., WE, K., K, J., WR, C., CU, M., & MN., S. (2025). Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.. J Prev Alzheimers Dis. https://doi.org/10.1016/j.tjpad.2024.100016

Source records

europe-pmc · retrieved 2026-09-26T03:22:22.133Z